Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • GMP Failures & Pharma Compliance
    • Common GMP Failures
    • GMP Documentation & Records Failures
    • Cleaning & Sanitation Failures in GMP Audits
    • HVAC, Environmental Monitoring & Cross-Contamination Risks
  • Toggle search form

Scan-to-PDF Practices: How to Avoid Losing Traceability and Metadata

Posted on November 21, 2025November 21, 2025 By digi


Scan-to-PDF Practices: How to Avoid Losing Traceability and Metadata

Ensuring Data Integrity in Scan-to-PDF Processes: A Step-by-Step Guide for Pharma Professionals

In pharmaceutical manufacturing and associated regulated environments, maintaining data integrity is paramount, especially when converting hardcopy GxP records into electronic formats such as PDF. The process of scanning to PDF, if not carefully executed, risks loss of critical traceability and metadata – a significant concern under regulatory frameworks including 21 CFR Part 11, Annex 11, and principles of ALCOA+. This comprehensive tutorial helps pharma QA, clinical operations, and regulatory affairs professionals in the US, UK, and EU to understand and implement compliant scan-to-PDF practices that preserve the authenticity, integrity, and usability of electronic records.

Step 1: Understanding Regulatory Expectations on Scan-to-PDF Practices

Before embarking

on the technical implementation of scanning paper records into PDF format, it is essential to appreciate the regulatory environment guiding these practices. Data integrity regulations underline that electronic documents must be trustworthy, reliable, and generally equivalent to their paper counterparts. Regulatory agencies such as FDA, EMA, and MHRA expect strict adherence to ALCOA+ principles—Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available—to ensure the quality and authenticity of electronic records.

The FDA’s guidance on electronic records and signatures, codified in 21 CFR Part 11, outlines requirements for electronic recordkeeping systems, including scan-to-PDF solutions. Similarly, EU GMP Annex 11 clarifies controls around computerized systems used in GMP-regulated environments, emphasizing system validation, audit trails, and protection against unauthorized changes. These regulations collectively require that scanned electronic versions of paper records maintain complete metadata and protect against data loss or alteration.

Failing to preserve metadata or traceability when scanning risks incomplete or non-reliable electronic GxP documentation, potentially leading to regulatory findings, delayed product release, or compliance gaps that impact patient safety. Therefore, pharma QA and regulatory affairs personnel must ensure that the chosen scan-to-PDF methodology aligns with these regulatory expectations from the onset.

Also Read:  Process Validation for Highly Potent Products and HPAPIs

Key Considerations

  • Metadata preservation: Document date/time, scanner ID, operator identity, and version history.
  • Audit trail capability: Transparent record of scanning, file creation, and modifications.
  • Validation and qualification: Confirming scanner and software performance meets regulatory requirements.
  • Access controls: Restricting scan and file update permissions to authorized personnel only.
  • Document lifecycle management: Retention and retrieval processes consistent with pharma GxP policies.

Step 2: Pre-Scan Preparation and Defining Standard Operating Procedures (SOPs)

To achieve a compliant scan-to-PDF process, organizations must design and document clear, controlled Standard Operating Procedures (SOPs) that govern preparation and scanning activities. This step helps to formalize controls, minimize the risk of data integrity breaches, and ensure consistent practice among operators.

SOPs should incorporate the following elements:

2.1 Document Selection and Verification

Prior to scanning, a meticulous review of paper GxP records is required to:

  • Ensure the document is complete, with no missing pages or illegible content.
  • Verify authenticity and original review/approval signatures, stamps, or annotations are intact.
  • Record document identifiers such as batch numbers, controlled document IDs, or version numbers.

2.2 Scanning Equipment Configuration and Validation

Pharma organizations must validate scanning equipment and software in line with their computerized system validation (CSV) policies. This includes:

  • Defining acceptable scan resolution (usually minimum 300 dpi for legibility).
  • Ensuring color depth and file format settings retain visual fidelity.
  • Configuring software to embed metadata such as scan date/time, operator ID, and document ID into the PDF.
  • Enabling audit trails for any document access or changes post-scan.
  • Validating that the scanning solution performs consistently within specification through test scans and periodic requalification.

2.3 Operator Training and Competency

It is critical that scanning operators receive formal data integrity training to understand:

  • The importance of maintaining ALCOA+ principles throughout the scan-to-PDF process.
  • How to properly handle paper documents and avoid contamination or damage.
  • The procedural steps required to scan documents correctly.
  • Accurate entry of metadata and completion of related documentation such as scan logs or checklists.
  • Procedures for escalating issues if scanning problems or data integrity risks are identified.

Evidence of operator training and competency assessment must be maintained as part of routine compliance documentation.

2.4 Environmental and Physical Controls

Scanning should occur in a controlled environment to minimize risks such as document damage, misplacement, or contamination. Considerations include:

  • Secure access to scanning areas to authorized personnel only.
  • Clean, dust-free workspaces to protect sensitive documents and scanners.
  • Use of document holders or feeders to prevent page loss or damage during scanning.
Also Read:  21 CFR Part 11 Compliance: Practical Implementation for Lab and Manufacturing Systems

Step 3: Performing the Scan-to-PDF Process in Compliance with Data Integrity Principles

With well-defined procedures and trained personnel, the actual scan-to-PDF activity must maintain rigorous control to ensure the electronic record’s fidelity and traceability. The following steps detail the operational approach:

3.1 Document Preparation

  • Inspect physical documents for damages such as folds, tears, pen marks, or stains that could obscure data.
  • Remove staples or bindings as per SOPs without affecting document order or integrity.
  • Verify any handwritten annotations or batch-specific remarks are clear and legible prior to scanning.

3.2 Scanning Execution

  • Use validated scanner settings: resolution, color mode, file format (PDF/A preferred for archival), and file naming conventions consistent with batch and document identifiers.
  • Scan single or multi-page documents sequentially, confirming that each scanned image accurately captures the original pages.
  • Ensure metadata capture is active within scanning software, documenting scan date/time, operator, scanner ID, and any software version used.
  • Immediately verify the quality of scanned output through manual review or automated image analysis tools.

3.3 Initial Verification and QC

  • Conduct an initial verification by a second qualified personnel who confirms that all pages have been scanned with full legibility, accuracy, and correct page order.
  • Cross-check embedded metadata with batch records or document identifiers.
  • Document any deviations or rescans, with appropriate justification and corrective actions documented as part of DL remediation if applicable.

3.4 File Management and Storage

  • Save scanned PDFs in a validated electronic document management system (EDMS) that conforms to 21 CFR Part 11 or Annex 11 standards, including requirements for electronic signatures and audit trails.
  • Immediately apply access controls to restrict modification or deletion to authorized personnel only.
  • Back up files through secure, validated electronic backup systems as part of GxP data backup policies.
  • Implement retention policies consistent with company and regulatory requirements for pharmaceutical records.

Step 4: Post-Scan Controls: Audit Trail Review and Ongoing Data Integrity Assurance

Post-scanning activities are crucial for ensuring that the digitized records remain fully compliant and trustworthy throughout their lifecycle. These include:

4.1 Audit Trail Review

Scanned PDF files and their management systems must generate audit trails that document all actions related to file creation, access, and modification. Pharma QA teams should regularly perform an audit trail review to detect:

  • Unauthorized access attempts or modifications.
  • Inconsistencies or unusual patterns in metadata changes.
  • Deviations from expected record lifecycle events.
Also Read:  21 CFR Part 11 Compliance: Electronic Records and Electronic Signatures Essentials

These reviews should be logged and, where applicable, trigger CAPA (Corrective and Preventive Actions) if data integrity issues are detected early.

4.2 Periodic System and Process Re-validation

To ensure ongoing compliance with regulatory expectations, companies must schedule periodic revalidation and qualification of scanning equipment and software. This confirms that the solutions continue to preserve metadata and document fidelity, accommodating any system upgrades or changes.

4.3 Data Integrity Training and Continuous Improvement

All personnel involved in scan-to-PDF processes must receive continuous data integrity training commensurate with role and responsibility. Training should highlight lessons learned, audit findings, and evolving requirements from regulatory bodies such as MHRA and WHO.

4.4 DL Remediation and Risk Management

If deficiencies are identified—such as loss of metadata or broken traceability—prompt Dl remediation measures must be initiated to restore compliant status. Risk assessment tools from ICH Q9 Quality Risk Management may be employed to prioritize remediation steps and mitigate recurrence effectively.

Step 5: Integrating Scan-to-PDF Processes into a Holistic Data Integrity Framework

Isolated control of scan-to-PDF processes is insufficient without embedding these within an integrated data governance and quality management system. The following strategic actions enable sustainable compliance:

5.1 Establishing Cross-Functional Teams

Collaborate across Quality Assurance, IT, Manufacturing, and Regulatory Affairs to develop harmonized and documented policies addressing the digitization of GxP records.

5.2 Leveraging Technology and Automation

Modern scanning solutions offer features such as automated metadata capture, barcode recognition, and integration with EDMS systems, reducing human error and easing compliance burdens.

5.3 Documentation and Change Control

All process updates, equipment changes, and software upgrades must be managed under documented change control procedures, ensuring traceability and regulatory alignment.

5.4 Monitoring and Continuous Audit

Deploy periodic system health checks, user access reviews, and reconciliation of scanned versus original paper records to proactively identify gaps.

Adopting a comprehensive approach supports robust pharma QA practices and ensures scanned PDFs remain accurate, legible, attributable, and compliant with global regulatory expectations.

Conclusion

Implementing compliant scan-to-PDF practices within pharmaceutical environments requires a structured, stepwise approach focused on maintaining data integrity and metadata traceability. By understanding regulatory requirements—including ALCOA+ principles, 21 CFR Part 11, and Annex 11—and applying rigorous SOPs, validation, operator training, and post-scan controls, pharma professionals can confidently convert paper GxP records to electronic formats without compromising data credibility. Continuous review, audit trail assessment, and remediation round out a robust system that meets US, UK, and EU expectations and supports patient safety through reliable documentation.

Data Integrity, ALCOA+ & Part 11 / Annex 11 Tags:ALCOA+, Annex 11, audit trail, data integrity, GxP compliance, Part 11, pharma QA

Post navigation

Previous Post: Spreadsheet Controls in GMP: Validation, Locking and Version Management
Next Post: Data Retention and Archiving Strategies That Protect Integrity Across the Lifecycle

Quick Guide

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog

Latest Posts

  • GMP-cGMP Regulations & Global Standards
    • FDA cGMP Regulations for Drugs & Biologics
    • cGMP Requirements for Pharmaceutical Manufacturers
    • ICH Q7 and API GMP Expectations
    • Global & ISO-Based GMP Standards
    • GMP for Medical Devices & Combination Products
    • GMP for Pharmacies & Hospital Pharmacy Settings
  • Applied GMP in Pharma Manufacturing & Operations
    • GMP for Pharmaceutical Drug Product Manufacturing
    • GMP for Biotech & Biologics Manufacturing
    • GMP Documentation
    • GMP Compliance
    • GMP for APIs & Bulk Drugs
    • GMP Training
  • Computer System Validation (CSV) & GxP Computerized Systems
    • CSV Fundamentals in Pharma & Biotech
    • FDA CSV Guidance & 21 CFR Part 11 Alignment
    • GAMP 5 & Risk-Based Validation Approaches
    • CSV in Pharmaceutical & GxP Industries (Use-Cases & System Types)
    • CSV Documentation
    • CSV for Regulated Equipment & Embedded Systems
  • Data Integrity & 21 CFR Part 11 Compliance
    • Data Integrity Principles in cGMP Environments
    • FDA Data Integrity Guidance & Expectations
    • 21 CFR Part 11 – Electronic Records & Signatures
    • Data Integrity in GxP Computerized Systems
    • Data Integrity Audits
  • Pharma GMP & Good Manufacturing Practice
    • FDA 483, Warning Letters & GMP Inspections
    • Data Integrity, ALCOA+ & Part 11 / Annex 11
    • Process Validation, CPV & Cleaning Validation
    • Contamination Control & Annex 1
    • PQS / QMS / Deviations / CAPA / OOS–OOT
    • Documentation, Batch Records & GDP
    • Sterility, Microbiology & Utilities
    • CSV, GAMP 5 & Automation
    • Dosage-Form–Specific GMP (Solids, Liquids, Sterile, Topicals)
    • Supply Chain, Warehousing, Cold Chain & GDP
Widget Image
  • Never Assign Batch Release Responsibilities to Non-QA Personnel in GMP

    Never Assign Batch Release Responsibilities… Read more

  • Manufacturing & Batch Control
    • GMP manufacturing process control
    • Batch Manufacturing record requirements
    • Master Batch record template for pharmaceuticals
    • In Process control checks in tablet manufacturing
    • Line clearance procedure before batch start
    • Batch reconciliation in pharmaceutical manufacturing
    • Yield reconciliation GMP guidelines
    • Segregation of different strength products GMP
    • GMP controls for high potency products
    • Cross Contamination prevention in manufacturing
    • Line clearance checklist for production
    • Batch documentation review before qa release
    • Process parameters control limits in pharma
    • Equipment changeover procedure GMP
    • Batch manufacturing deviation handling
    • GMP expectations for batch release
    • In Process sampling plan for tablets
    • Visual inspection of dosage forms GMP requirements
    • In Process checks for filled vials
    • Startup and Shutdown procedure for manufacturing line
    • GMP requirements for blending and mixing operations
    • Process Control strategy in pharmaceutical manufacturing
    • Uniformity of dosage units in process controls
    • GMP checklist for oral solid dosage manufacturing
    • Process Control
    • Batch Documentation
    • Master Batch Records
    • In-Process Controls
    • Line Clearance
    • Yield & Reconciliation
    • Segregation & Mix-Ups
    • High Potency Products
    • Cross Contamination Control
    • Line Clearance
    • Batch Review
    • Process Parameters
    • Equipment Changeover
    • Deviations
    • Batch Release
    • In-Process Sampling
    • Visual Inspection
    • In-Process Checks for Vials
    • Start-Up & Shutdown
    • Blending & Mixing
    • Control Strategy
    • Dosage Uniformity
    • Hold Time Studies
    • OSD GMP Checklist
  • Cleaning & Contamination Control
  • Warehouse & Material Handling
    • Warehouse GMP
    • Material Receipt
    • Sampling
    • Status Labelling
    • Storage Conditions
    • Rejected & Returned
    • Reconciliation
    • Controlled Drugs
    • Dispensing
    • FIFO & FEFO
    • Cold Chain
    • Segregation
    • Pest Control
    • Env Monitoring
    • Palletization
    • Damaged Containers
    • Stock Verification
    • Sampling & Weighing Areas
    • Issue to Production
    • Traceability
    • Printed Materials
    • Intermediates
    • Cleaning & Housekeeping
    • Status Tags
    • Warehouse Audit
  • QC Laboratory & Testing
    • Analytical Method Validation
    • Chromatography Systems
    • Dissolution Testing
    • Assay & CU
    • Impurity Profiling
    • Stability & QC
    • OOS Investigations
    • OOT Trending
    • Sample Management
    • Reference Standards
    • Equipment Calibration
    • Instrument Qualification
    • LIMS & Electronic Data
    • Data Integrity
    • Microbiology QC
    • Sterility & Endotoxin
    • Environmental Monitoring
    • QC Documentation
    • Results Review
    • Method Transfer
    • Forced Degradation
    • Compendial Methods
    • Cleaning Verification
    • QC Deviations & CAPA
    • QC Lab Audits
  • Manufacturing & In-Process Control
    • Batch Manufacturing Records
    • Batch Manufacturing Records
    • Line Clearance
    • In-Process Sampling & Testing
    • Yield & Reconciliation
    • Granulation Controls
    • Blending & Mixing
    • Tablet Compression Controls
    • Capsule Filling Controls
    • Coating Process Controls
    • Sterile & Aseptic Processing
    • Filtration & Sterile Filtration
    • Visual Inspection of Parenteral
    • Packaging & Labelling Controls
    • Rework & Reprocessing
    • Hold Time for Bulk & Intermediates
    • Manufacturing Deviations & CAPA
  • Documentation, Training & QMS
    • SOP & Documentation Control
    • Training & Competency Management
    • Change Control & QMS Lifecycle
    • Internal Audits & Self-Inspection
    • Quality Metrics, Risk & Management Review
  • Production SOPs
  • QC Laboratory SOPs
    • Sample Management
    • Analytical Methods
    • HPLC & Chromatography
    • OOS & OOT
    • Data Integrity
    • Documentation
    • Equipment
  • Warehouse & Materials SOPs
    • Material Receipt
    • Sampling
    • Storage
    • Dispensing
    • Rejected & Returned
    • Cold Chain
    • Stock Control
    • Printed Materials
    • Pest & Housekeeping
  • Cleaning & Sanitization SOPs
  • Equipment & Qualification SOPs
  • Documentation & Data Integrity SOPs
  • Deviation/OOS/CAPA SOPs
    • Deviation Management
    • Root Cause
    • CAPA
    • OOS/OOT
    • Complaints
    • Recall
  • Training & Competency SOPs
    • Training System
    • Role-Based Training
    • OJT
    • Refresher Training
    • Competency
  • QA & QMS Governance SOPs
    • Quality Manual
    • Management Review
    • Internal Audit
    • Risk Management
    • Vendors & Outsourcing
  • About Us
  • Privacy Policy & Disclaimer
  • Contact Us

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme